Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk
Sponsor: Joslin Diabetes Center
A PHASE2/PHASE3 clinical study on Atherosclerosis and Cardiovascular Disease, this trial is completed. The trial is conducted by Joslin Diabetes Center and has accumulated 11 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Aug 2018 — Feb 2020 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Joslin Diabetes Center
- VA Office of Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .